InvestorsHub Logo
Followers 5
Posts 2589
Boards Moderated 0
Alias Born 07/18/2006

Re: Aiming4 post# 11232

Monday, 10/15/2007 8:23:43 AM

Monday, October 15, 2007 8:23:43 AM

Post# of 52269
I keep going back to the conversation I had with Roger on wednesday, I sensed disappointment but not desperation and I think with the money sloshing around BP looking for hope out there , our future lies in a larger Global partnership. Cortex would be working "for" someone again- but it would insure that those massive options retain value. Aiming's points are what I think needs to be viewed with some favorability and likeliness. I note Ron Garren sold....( he never traded it well anyway) and joined Piros in recommending the selling of the company. He also said the target remains an exciting one and that Cortex does not have the 'horsepower' ( his word) to develop it. I think he is right sans bigger deal with a Schering Plough, Pfizer ect....- Say Stoll has one in his back pocket....they all wanted CX-717 alongside the high impact deal he walked away from- and assume they wanted CX-717 for ADHD only. He told me straight up CX-701 was not dead for ADHD,I asked is CX-701 dead for ADHD? his words..." Oh no, it would probably go gangbusters in that"......So, what can you read from that? I think the tox issue with CX-717 and it's initial occurence was it's own lead ballon. It had too high a MG count/ small a half-life to work at low doses, plus....think Vioxx, it had tox issues that were glossed over in an earlier period, pre-clinical. That is now and forever the rule of thumb.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RSPI News